CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 183 enrolled
Drug / intervention
PF-04236921 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01405196
NCT01405196Phase 2Completed
CompareCT.gov

A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)

Pfizer·interventional·Posted Jul 29, 2011·Updated Dec 19, 2017

In Brief

A Phase 2 clinical trial evaluating PF-04236921 for Lupus Erythematosus, Systemic. Completed, enrolled 183 participants across 113 sites in 13 countries.

Detailed Summary

The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory measures as well.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus, Systemic
CountriesArgentina, Chile, Colombia, Germany, Hungary, Moldova, Peru, Poland, Puerto Rico, Romania, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 29, 2011
Enrollment StartDec 1, 2011
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.9 years ago

Interventions

PF-04236921biological

subcutaneous injection; administered at day 1, weeks 8, 16.

PF-04236921biological

subcutaneous injection; administered at day 1, weeks 8, 16.

PF-04236921biological

subcutaneous injection; administered at day 1, weeks 8, 16.

PF-04236921biological

subcutaneous injection; administered at day 1, weeks 8, 16